News

Crystal Stone and Amanda Coogan of Remarque Systems discuss how an RBM approach can help enhance the safety and efficiency of clinical trials.

Kyle Hogan, Director, eClinical Solutions, Clinical Ink, writes how however promising ePRO may be - its benefits may not be enough to overcome concerns that take an significant period of investment before generating business, patient benefits, and financial returns.

The case for evaluating drugs with real-world digital health data.

Abby Abraham, Vice President, Data Analytics, and RBM for OmniComm Systems, writes about a new survey that highlights gaps in the conversation surrounding the industry’s adoption and implementation of risk-based approaches to monitoring.

Moe Alsumidaie sits down with Ping Yeh, CEO and co-founder of StemoniX, to discuss how MicroOrgans will transform preclinical and clinical development in challenging areas like Alzheimer’s.

At some point in every organization’s life, they come to realize that their data environment isn’t set up for success. Adrian Cottrell, PhD, VP of clinical, medical, and regulatory tech for GlaxoSmithKline writes about when his company came to that very conclusion in 2017.